目的 探讨美沙拉嗪与柳氮磺吡啶治疗溃疡性结肠炎的临床疗效。方法 将82例溃疡性结肠炎患者随机分为治疗组和对照组,治疗组42例,对照组40例。治疗组给予美沙拉嗪,对照组给予柳氮磺胺吡啶,治疗疗程均为6个月。比较两组的疗效和不良反应发生情况。结果 对照组临床总有效率67.5%,治疗组总有效率为83.3%,两组比较差异显著(P<0.05)。腹泻、腹痛、黏液血便,治疗组的总有效率分别为85.4%、86.8%和91.7%,对照组分别为78.9%、75.7%、73.5%。与对照组相比,治疗组腹泻、腹痛、黏液血便等疗效改善情况明显较好(P<0.05);与对照组相比,治疗组不良反应发生率明显较低(P<0.05)。结论 美沙拉嗪治疗溃疡性结肠炎疗效确切,不良反应发生率低,值得临床推广。
Objective To compare the clinical curative effect in the treatment of ulcerative colitis in active phase with mesalazine and salazosulfapyridine. Methods Patients (82 cases) with ulcerative colitis were randomly divided into mesalazine group (42 cases) and salazosulfapyridine group, the groups were respectively given the mesalazine and salazosulfapyridine treatment for a course of 6 months. The curative effect and adverse reactions in two groups were observed. Results The total effective rate of control group was 67.5%, the total effective rate of treatment group was 83.3%, and there was significant difference between the two groups (P < 0.05). Total effective rates of treating diarrhea, abdominal pain, and mucous bloody stool in mesalazine group were 85.4%, 86.8%, and 91.7%, respectively and those in salazosulfapyridine group were 78.9%, 75.7%, and 73.5%, respectively. Comparing the two groups there was no significant difference in diarrhea curative effect, but in abdominal pain, mucous bloody stool efficacy improvement the mesalazine was superior to the salazosulfapyridine group (P < 0.05); The incidence of adverse reactions was 14.3% in mesalazine group, which was obviously lower than the incidence of 22.5% in salazosulfapyridine group, the comparison showed significant difference (P < 0.05). Conclusion Mesalazine for the treatment of ulcerative colitis shows a definite curative effect and lower incidence of adverse reactions, so it is worthy of clinical promotion.